CAR-T and ibrutinib vs CLL: sequential or simultaneous?

doi:10.1182/blood.2020005362

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P Kater, J Joseph Melenhorst

Abstract

No abstract listed.

References

Dec 19, 2012·Blood·John C RichesJohn G Gribben

Sep 4, 2015·Science Translational Medicine·David L PorterCarl H June

Jan 28, 2016·Blood·Joseph A FraiettaMarcela V Maus

Jul 18, 2017·The Journal of Clinical Investigation·Meixiao LongJohn C Byrd

Jul 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron J TurtleDavid G Maloney

May 2, 2018·Nature Medicine·Joseph A FraiettaJ Joseph Melenhorst

Sep 15, 2018·Blood·Iris de WeerdtArnon P Kater

May 12, 2019·Blood·Jaco A C van BruggenGerritje J W van der Windt

Sep 12, 2019·Blood Advances·Iris de WeerdtArnon P Kater

Feb 23, 2020·Blood·Jordan GauthierCameron J Turtle

Citations

Sep 24, 2020·Cancer Cell International·Biqin TanNengming Lin

Jul 3, 2021·Cancers·Elisavet VlachonikolaAnastasia Chatzidimitriou

Related Concepts

Related Feeds

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Abstract

References

Citations

Related Concepts

Related Feeds

Related Papers

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Abstract

References

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Ibrutinib treatment improves T cell number and function in CLL patients

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.

Citations

The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia.

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

Related Papers

Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.

Five years of ibrutinib in CLL.

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

Ibrutinib: targeting the hidden CLL.

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway